Effect of homocysteine lowering by 5-methyltetrahydrofolate on redox status in hyperhomocysteinemia

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 4, 2006, Pages 549-555

  Caruso, Raffaele ^a   Campolo, Jonica ^a   Sedda, Valentina ^a   De Chiara, Benedetta ^a   Dellanoce, Cinzia ^a   Baudo, Francesco ^a   Tonini, Annamaria ^a   Parolini, Marina ^a   Cighetti, Giuliana ^b   Parodi, Oberdan ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antioxidants; Folate; Free radicals; Glutathione; Homocysteine

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CYANOCOBALAMIN; CYSTEINYLGLYCINE; FOLIC ACID; GLUTATHIONE; HOMOCYSTEINE; MALONALDEHYDE; ORAL CONTRACEPTIVE AGENT; PREFOLIC; THIOL DERIVATIVE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; LINEAR REGRESSION ANALYSIS; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN METABOLISM; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIOXIDANTS; ASCORBIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATION-REDUCTION; SULFHYDRYL COMPOUNDS; TETRAHYDROFOLATES; VITAMIN B 12; VITAMIN E;

EID: 33748202478     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211748.16573.31     Document Type: Article

References (34)

1. Chambers JC, McGregor A, Jean-Marie J, et al. Demonstration of rapid onset vascular endothelial dysfunction after hyper-homocysteinemia. An effect reversible with vitamin C therapy. Circulation. 1999;99:1156-1160.
2. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
3. Malinow MR. Plasma Homocyst(e)ine and arterial occlusive diseases: a mini-review. Clin Chem. 1994;40:173-176.
4. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
5. Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem. 1997;272:25380-25385.
6. Yamamoto M, Hara H, Adachi T. Effect of homocysteine on the binding of extracellular-super-oxide dismutase to the endothelial cell surface. FEBS Lett. 2000;486:159-162.
7. Rodrigo R, Passalacqua W, Araya J, et al. Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J Cardiovasc Pharmacol. 2003;42:453-461.
8. Schnabel R, Lackner KJ, Rupprecht HJ, et al. Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction. J Am Coll Cardiol. 2005;45:1631-1637.
9. El-Khairy L, Ueland PM, Refsum H, et al. Plasma cysteine as a risk factor for cardiovascular disease. Circulation. 2001;103:2544-2549.
10. Moat SJ, Lang D, McDowell IFW, et al. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem. 2004;15:64-79.
11. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol. 2003;41:2105-2113.
12. Doshi SN, Mc Dowell IFW, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation. 2002;105:22-26.
13. Apeland T, Mansoor MA, Seljeflot I, et al. Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low-dose folinic acid therapy. J Int Med. 2002;252:456-464.
14. Verhaar M, Wever RMF, Pharm D, et al. 5-methyltetrahidrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 1998;97:237-241.
15. Rezk BM, Haenen GR, van der Vijgh WJ, et al. Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification on the antioxidant pharmacophore. FEBS Lett. 2003;555:601-605.
16. Loscalzo J. Folate and nitrate-induced endothelial dysfunction. A simple treatment for a complex pathobiology. Circulation. 2001;104:1086-1088.
17. Medina MA, Urdiales JL, Sánchez-Amores MI. Roles of homocysteine in cell metabolism. Eur J Biochem. 2001;268:3871-3882.
18. De Chiara B, Bigi R, Campolo J, et al. Blood glutathione as a marker of cardiac allograft vasculopathy in heart transplant recipients. Clin Transplant. 2005;19:367-371.
19. Accinni R, Parodi O. Determination of plasma homocysteine. In: Drew AF, ed. Atherosclerosis: Experimental Methods and Protocols. Totowa, NJ: Humana Press; 2001:77-103.
20. Cighetti G, Debiasi S, Paroni R, et al. Free and total malondialdehyde assessment in biological matrices by gas chromatography-mass spectrometry: what is needed for an accurate detection. Anal Biochem. 1999;266:222-229.
21. Hultqvist M, Hegbrant J, Nilsson-Thorell C, et al. Plasma concentration of vitamin C, vitamin E and/or malondialdehyde as markers of oxygen free radical production during hemodialysis. Clin Nephrol. 1997;47:37-46.
22. Kang SS, Wong PW, Susmano A, et al. Thermolabile methylenetethrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991;48:536-545.
23. Doshi SN, McDowell IF, Moat SJ, et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular super-oxide? Arterioscler Thromb Vasc Biol. 2001;21:1196-1202.
24. Coppola A, D'Angelo A, Fermo I, et al. Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methyltetrahydrofolate reductase genotype. Br J Haematol. 2005;131:100-108.
25. Mayer O, Filiposký J, Hromádka M, et al. Treatment of hyperhomocysteinemia with folic acid: effects on homocysteine levels, coagulation status, and oxidative stress markers. J Cardiovasc Pharmacol. 2002;39:851-857.
26. Williams RH, Maggiore JA, Reynolds RD, et al. Novel approach for determination of the redox status of homocysteine and other aminothiols in plasma from healthy subjects and patients with ischemic stroke. Clin Chem. 2001;47:1031-1039.
27. Jonasson T, Ohlin AK, Gottsater A, et al. Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease - a prospective randomized study of vitamin supplementation. Clin Chem Lab Med. 2005;43:628-634.
28. Upchurch GR, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272:17012-17017.
29. Weiss N, Zhang YY, Heydrick S, et al. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci U S A. 2001;98:12503-12508.
30. Cafolla A, Dragoni F, Girelli G, et al. Effect of folic acid and vitamin C supplementation on folate status and homocysteine level: a randomised controlled trial in Italian smoker-blood donors. Atherosclerosis. 2002;163:105-111.
31. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocystine: a meta-analysis of the randomized trials. Am J Clin Nutr. 2005;82:806-812.
32. 12 in health and disease. Nutr Rev. 2004;62:S3-S12.
33. Willems FF, Boers GH, Blom HJ, et al. Pharmacokinetic study on the utilization of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. Br J Pharmacol. 2004;141:825-830.
34. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on casuality from a meta-analysis. Br Med J. 2002;235:1202-1206.